The latest Fact.MR study indicates healthcare facilities, contract research organizations, and educational & research institutes collectively spent ~US$ 1,950 Mn on eCOA, eSource and clinical trials solutions in 2018. The eCOA, eSource & clinical trials market is envisaged to witness substantial traction through 2019, with gains primarily driven by the growing penetration of digitization in healthcare sector and substantial increase in pharma spending on clinical trials.
Request for the Report Summary: https://www.factmr.com/report/4042/ecoa-esource-clinical-trials-market
Rapidly expanding deployment of clinical trial solutions, which contributed to ~40% of the total spending on eCOA, eSource, and clinical trials in 2018, will continue to appeal a widening bandwidth of institutions through 2029, says the report.
The Fact.MR study opines that though the deployment of clinical trial solutions overshadowed the use of Electronic Clinical Outcome Assessment (eCOA), eSource, and EDA in 2018, the market is envisaged to witness a range of changes during the foreseeable period. Growing penetration of Bring Your Own Device (BYOD) trend in clinical trials is highly likely to pace up the use of eCOAs, such as ePROS, ClinROs, ObsROs, and PerfORs across wide range of pharmaceutical companies and research facilities.
eCOAs is envisaged to hold ~45% of the overall spending share by the end of 2029, in line with the growing use of smartphones and tablets to seamlessly collect clinical data for analysis. Additionally, reduced cost and high scalability of eCOA are the primary determinants that continue to push its adoption during clinical trials, which is envisaged to contribute significantly to the growth of the eCOA, eSource & clinical trials market.
Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4042
As the healthcare sector delves deeper into advanced technology, a large number of companies have formulated unique strategies to remain unaffected by the curve of change. Several pharmaceutical companies, research organizations and CROs have placed their focus on collaborations, while they embrace digitization to create patient-centric experiences. For instance, Signant Health has launched a partner program to collaborate with Clinical Research Organizations (CROs) that are dedicated towards improving clinical trials using patient-centric technology.
Additionally, Iqvia has recently launched a novel eCOA cloud based technology platform to quantify the patient experience, while increasing efficiency and reducing timelines at the same time. As per the Fact.MR study, the increasing prevalence of various chronic infectious diseases has led to a dire unmet need for efficient clinical trials in developing countries. Moreover the rising medical expense in these regions, which can be attributed to the fact that private hospitals are the key healthcare providers herein, continue to fuel clinical trial participation in developing countries. This, coupled with the growing awareness about the cost and efficiency benefits of using eCOA, eSource & clinical trial solutions for conducting clinic trials, and comparatively lenient regulatory framework are likely to add to the lucrativeness of developing countries, such as China and India for market players.
Request for the Report Customization: https://www.factmr.com/connectus/sample?flag=RC&rep_id=4042
About Us
Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level â€" our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.
Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.
The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.
Contact Us
FactMR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Tel: +353-1-4434-232
Tel: +353-1-6111-593
Email: sales@factmr.com
Blog: https://theheraldmedia.com/